Orchard Therapeutics plc

NasdaqCM:ORTX 주식 보고서

시가총액: US$380.1m

Orchard Therapeutics 미래 성장

Future 기준 확인 2/6

Orchard Therapeutics은 연간 수입과 매출이 각각 12.5%와 34.5% 증가할 것으로 예상되고 EPS는 연간 55.2%만큼 증가할 것으로 예상됩니다.

주요 정보

12.5%

수익 성장률

55.2%

EPS 성장률

Biotechs 수익 성장28.3%
매출 성장률34.5%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트15 Dec 2023

최근 미래 성장 업데이트

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

May 09
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Mar 10
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Aug 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03
What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08
Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11
Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

수익 및 매출 성장 예측

NasdaqCM:ORTX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026152-50-106N/A2
12/31/202597-75-148N/A2
12/31/202454-115-129-1143
12/31/202328-93-85-853
9/30/202322-73-94-93N/A
6/30/202321-85-93-87N/A
3/31/202318-124-93-86N/A
12/31/202223-151-83-76N/A
9/30/202216-179-104-97N/A
6/30/202212-168-100-96N/A
3/31/20227-154-109-105N/A
12/31/20212-145-128-125N/A
9/30/20211-142-106-104N/A
6/30/20212-126-115-114N/A
3/31/20213-137-117-116N/A
12/31/20203-152-139-126N/A
9/30/20203-164-171-155N/A
6/30/20203-180-197-181N/A
3/31/20203-183-187-172N/A
12/31/20193-163-170-166N/A
9/30/20193-143-153-151N/A
6/30/20192-140-131-130N/A
3/31/20192-246-129-127N/A
12/31/20182-230-102-98N/A
9/30/20181-219-85-81N/A
6/30/2018N/A-198-63-59N/A
3/31/2018N/A-48-43-40N/A
12/31/2017N/A-40-34-32N/A

애널리스트 미래 성장 예측

수입 대 저축률: ORTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ORTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ORTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ORTX 의 수익(연간 34.5% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: ORTX 의 수익(연간 34.5% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: ORTX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.


성장 기업 발견